Markets:

Overview

News

Currencies

International

Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

773.79 +1.92 (+0.25%)

Streaming Delayed Price Updated: 12:11 PM EST, Jan 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Regeneron Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9

...

48 49 Next >

Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026

December 31, 2025

As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the...

Via MarketMinute

3 Reasons to Avoid REGN and 1 Stock to Buy Instead

December 30, 2025

What a fantastic six months it’s been for Regeneron. Shares of the company have skyrocketed 47.6%, hitting $774.98. This was partly due to its solid quarterly results, and the performance may have...

Via StockStory

Discover which S&P500 stocks are making waves on Tuesday. ↗

December 30, 2025

Curious about the S&P500 stocks that are in motion on Tuesday? Join us as we explore the top movers within the S&P500 index during today's session.

Via Chartmill

3 Cash-Heavy Stocks We Approach with Caution

December 28, 2025

A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow.

Via StockStory

The Vaccine Vanguard: Inside Sanofi’s $2.2 Billion Strategic Bet on Dynavax

December 25, 2025

As 2025 draws to a close, the global pharmaceutical landscape has been reshaped by a series of aggressive consolidations and strategic pivots. At the center of this transformation is Sanofi (NASDAQ:...

Via PredictStreet

Topics Artificial Intelligence Economy Intellectual Property

The Atomic Architect: How University of Washington’s Generative AI Just Rewrote the Rules of Medicine

December 24, 2025

In a milestone that many scientists once considered a "pipe dream" for the next decade, researchers at the University of Washington’s (UW) Institute for Protein Design (IPD) announced in late 2025 the...

Via TokenRing AI

Topics Artificial Intelligence

Sanofi’s $2.2 Billion Strategic Pivot: Deconstructing the Dynavax Acquisition and the Future of Specialty Medicine

December 24, 2025

As of today, December 24, 2025, the global pharmaceutical landscape is witnessing a profound consolidation of power within specialty medicine and immunology. Sanofi (NASDAQ: SNY; Euronext: SAN), the...

Via PredictStreet

Topics Artificial Intelligence Economy Intellectual Property

AbbVie, Merck, Other Top Drugmakers To Lower Prices Of US Drugs In MFN Deal With Trump Administration: Report ↗

December 19, 2025

This comes after President Donald Trump urged drugmakers in July to lower drug prices for the U.S. government’s Medicaid program.

Via Stocktwits

Topics Economy Government

Novartis US Stock Rises On Reports Of White House Pricing Deal Due Friday — Roche Also In Talks ↗

December 17, 2025

The potential agreements would mark another step in Washington’s broader effort to reshape drug pricing.

Via Stocktwits

Topics Government World Trade

Pfizer Adds to Its Big Bet on Weight Loss Drugs ↗

December 16, 2025

Via MarketBeat

2 Large-Cap Stocks on Our Buy List and 1 We Find Risky

December 15, 2025

Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it more challenging to maintain high growth...

Via StockStory

2 Reasons to Buy Regeneron Stock Like There's No Tomorrow ↗

December 13, 2025

Look beyond the healthcare company's recent setbacks.

Via The Motley Fool

3 Low-Volatility Stocks We’re Skeptical Of

December 10, 2025

Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.

Via StockStory

Beyond AI: How Non-AI Tech Innovations are Fueling a New Era of Stock Market Growth

December 11, 2025

As 2025 draws to a close, a powerful undercurrent of technological innovation, extending far beyond the pervasive influence of artificial intelligence, is demonstrably reshaping the global stock...

Via MarketMinute

Topics Artificial Intelligence Economy Emissions

Is Alnylam Pharmaceuticals a Millionaire Maker? ↗

December 07, 2025

This hot biotech stock could have a lot more room to run.

Via The Motley Fool

3 Cash-Producing Stocks We Find Risky

December 03, 2025

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak...

Via StockStory

Morgan Stanley Downgrades Regeneron (REGN) to Equal-Weight, Citing Fair Valuation and Pipeline Scrutiny

December 03, 2025

New York, NY – December 3, 2025 – In a significant move reverberating through the biotechnology sector, investment banking giant Morgan Stanley has downgraded Regeneron Pharmaceuticals (NASDAQ: REGN)...

Via MarketMinute

Topics Intellectual Property

Exploring the top movers within the S&P500 index during today's session. ↗

December 01, 2025

Curious about the top performers within the S&P500 index one hour before the close of the markets on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive...

Via Chartmill

5 Healthcare Names to Watch as Sector Rotation Is in Full Swing ↗

December 01, 2025

Via MarketBeat

Should You Buy This Biotech Stock That Just Gained 5% in 1 Day? ↗

November 30, 2025

The comeback may have begun.

Via The Motley Fool

1 Reason Why Shares of Regeneron Pharmaceuticals Are Surging This Month ↗

November 24, 2025

Markets are dipping lower this month, but positive news from the FDA has this biotech stock ripping higher.

Via The Motley Fool

Mettler-Toledo, Agilent, Waters Corporation, Merck, and Regeneron Shares Skyrocket, What You Need To Know

November 21, 2025

A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated...

Via StockStory

Topics Economy World Trade

3 Nasdaq 100 Stocks We Keep Off Our Radar

November 21, 2025

The Nasdaq 100 (^NDX) is known for housing some of the most innovative and fastest-growing companies in the market. But not every stock in the index is a winner - some are struggling with slowing...

Via StockStory

Let's take a look at the S&P500 stocks that are experiencing unusual volume in today's session. ↗

November 20, 2025

Curious about which S&P500 stocks are generating unusual volume on Thursday? Find out below.

Via Chartmill

Tech Stocks Fall Despite Nvidia's Beat, Walmart Jumps 6%: What's Moving Markets Thursday? ↗

November 20, 2025

Nvidia Corp. (NASDAQ:NVDA) delivered another blockbuster quarter and raised its outlook, but even that wasn't enough to lift Wall Street on Thursday.

Via Benzinga

What's going on in today's session: S&P500 movers ↗

November 20, 2025

Curious about the S&P500 stocks that are in motion on Thursday? Join us as we explore the top movers within the S&P500 index during today's session.

Via Chartmill

Regeneron Wins FDA Nod For Eylea HD With Reduced Injection Schedule For Patients With Vision Loss ↗

November 20, 2025

FDA approves Regeneron's Eylea HD for retinal vein occlusion, adding extended dosing options and greater flexibility across multiple eye disease indications.

Via Benzinga

Which S&P500 stocks are moving before the opening bell on Thursday? ↗

November 20, 2025

Before the US market kicks off on Thursday, let's examine the pre-market session and unveil the notable performers among the S&P500 top gainers and losers.

Via Chartmill

Wall Street Braces for Impact as Delayed Jobs Report Emerges from Data Blackout

November 19, 2025

New York, NY – November 19, 2025 – Wall Street is on high alert as the highly anticipated September 2025 jobs report, a critical barometer of the nation's economic health, is finally set to be released...

Via MarketMinute

Topics Artificial Intelligence Bonds Economy

Regeneron Pharmaceuticals (NASDAQ:REGN) Screens as a Compelling Value Investment ↗

November 18, 2025

Regeneron (REGN) appears undervalued with a low P/E ratio, strong profitability, and a rock-solid financial health profile. A compelling value stock.

Via Chartmill

< Previous 1 2 3 4 5 6 7 8 9

...

48 49 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.